Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease

Alessandra R. Souza, Claudia M. Maruyama, Marco Aurélio P. Sáfadi, Marta H. Lopes, Raymundo S. Azevedo, Helen Findlow, Xilian Bai, Raymond Borrow, Lily Y. Weckx*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Background A decline of protective antibody titers after MCC vaccine has been demonstrated in healthy children, this may be an issue of concern for risk groups. The aim of this study was to evaluate the persistence of bactericidal antibodies after MCC vaccine in sickle cell disease (SCD) patients. The type of vaccine used and booster response were also analyzed. Methods SCD patients (n = 141) previously immunized with MCC vaccines had blood drawn 2–8 years after the last priming dose. They were distributed according to age at primary immunization into groups: <2 years and 2–13 years and evaluated by years since vaccination (2–3, 4–5 and 6–8). Serum bactericidal antibodies with baby rabbit complement (rSBA) and serogroup C-specific IgG concentrations were measured. The correlate of protection was rSBA titer ⩾8. Subjects with rSBA <8 received a booster dose and antibody levels re-evaluated after 4–6 weeks. Results For children primed under 2 years of age rSBA titer ⩾8 was demonstrated in 53.3%, 21.7% and 35.0%, 2–3, 4–5, 6–8 years, respectively, after vaccination, compared with 70.0%, 45.0% and 53.5%, respectively, for individuals primed at ages 2–13 years. rSBA median titers and IgG median levels were higher in the older group. Six to eight years after vaccination the percentage of patients with rSBA titers ⩾8 was significantly higher in the group primed with MCC-TT (78.5%) compared with those primed with MCC-CRM197 [Menjugate® (33.3%) or Meningitec® (35.7%)] (p = 0.033). After a booster, 98% achieved rSBA titer ⩾8. Conclusion Immunity to meningococcal serogroup C in SCD children declines rapidly after vaccination and is dependent on the age at priming. Booster doses are needed to maintain protection in SCD patients. Persistence of antibodies seems to be longer in individuals primed with MCC-TT vaccine comparing to those immunized with MCC-CRM197.

Original languageEnglish
Pages (from-to)4327-4334
Number of pages8
Issue number36
Publication statusPublished - 5 Aug 2016

Bibliographical note

Funding Information:
This project was partially funded by the Global Infectious Diseases Research and Training Program (Fogarty International Center-National Institutes of Health, D43TWW006592) and Fundação de Apoio à Universidade Federal de São Paulo (FAP).

Funding Information:
Helen Findlow, Xilian Bai and Ray Borrow perform contract research on behalf of Public Health England for GSK, Novartis, Pfizer and Sanofi Pasteur. Marco Aurélio Palazzi Sáfadi has received grants to support research projects from GSK, Novartis, Sanofi Pasteur and Pfizer. Lily Yin Weckx has received research grants on befalf of Universidade Federal de São Paulo from GSK, Novartis, MSD and Pfizer.

Publisher Copyright:
© 2016 Elsevier Ltd


  • Conjugate vaccines
  • Meningococcal infections
  • Meningococcal vaccines
  • Serum bactericidal antibody assay
  • Sickle cell disease


Dive into the research topics of 'Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease'. Together they form a unique fingerprint.

Cite this